Promising Phase 2 Results for Invikafusp Alfa
Marengo Therapeutics, Inc., a leading company in precision immunotherapies, has disclosed exciting Phase 2 results for its investigational treatment, invikafusp alfa, during a key presentation at the European Society for Medical Oncology's (ESMO) annual meeting. This trial showcases significant findings related to the effectiveness of invikafusp alfa across several solid tumor types that have shown resistance to PD-1 therapies.
Key Efficacy Metrics in Solid Tumors
Among the interim results shared, a notable 20.5% overall response rate (ORR) was achieved in heavily pre-treated tumors characterized by high mutational burden (TMB-H) or microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR). The study reinforced the drug's potential across six major solid tumor types: colorectal, lung, breast, gastric, gastroesophageal junction (GEJ), and head and neck cancers, where a 79% disease control rate was recorded.
Data collected up until the cutoff indicated that over half, specifically 52%, of the patients experienced tumor shrinkage, signaling a strong PD-1 independent activity observed from this monotherapy. This is a positive indication towards addressing the needs of patients with limited treatment options.
Understanding the Mechanism of Action
The data further validate the innovative approach employed by Marengo, which involves selectively activating distinct T-cell subsets (V?6/V?10). By doing so, invikafusp alfa seeks to tap into unique immune biology that could lead to better responses from patients who previously struggled with other immunotherapies. Zhen Su, M.D., CEO of Marengo, remarked on the potential of this treatment to serve as a backbone for pan-tumor immunotherapy, particularly in targeting resistant tumors.
Next Steps for Marengo
In light of these promising results, Marengo Therapeutics is keen to push forward with a biomarker-enriched strategy involving invikafusp alfa. This includes additional studies aimed at understanding the depth and durability of the therapeutic response in patients presenting TMB-H or MSI-H/dMMR solid tumors. The company has also secured Fast Track designation from the U.S. FDA for TMB-H microsatellite metastatic colorectal cancer (mCRC), which opens avenues for expedited regulatory interactions.
In its commitment to broaden the treatment landscape, Marengo plans to explore a combination of invikafusp alfa with Trodelvy® (a TROP2-directed antibody-drug conjugate) in treating triple-negative breast cancer (TNBC) and HR+/HER2– breast cancer, capitalizing on synergy in immuno-oncology settings.
About Invikafusp Alfa
Invikafusp alfa stands out as a first-in-class bispecific dual T-cell agonist, designed to specifically activate and enhance T-cell subsets that are crucial for anti-tumor responses. This novel therapeutic strategy aims to restore immune responses in patients whose previous treatments have encountered limitations. The results presented at ESMO mark a significant milestone in its clinical evaluation, following earlier disclosures of its efficacy.
About Marengo Therapeutics
Marengo Therapeutics, Inc. focuses on developing innovative T-cell targeting strategies that work to combat cancer and autoimmune disorders. Their work is supported by advanced platforms dedicated to selectively activating relevant T-cell populations, ensuring a comprehensive approach to treatment in oncology.
Frequently Asked Questions
What is invikafusp alfa?
Invikafusp alfa is a bispecific dual T-cell agonist designed to activate specific T-cell subsets to enhance anti-tumor immunity.
What were the key results from the Phase 2 trial?
The trial showed a 20.5% overall response rate and a 79% disease control rate in extensively pre-treated tumors.
How does Marengo Therapeutics plan to advance this research?
The company intends to continue the Phase 2 expansion in TMB-H or MSI-H/dMMR tumors while pursuing combination studies and regulatory approval.
What significance do these findings hold for patients?
These findings indicate a promising treatment option for patients with PD-1 resistant tumors, offering new hope for effective therapeutic strategies.
What is the long-term goal of Marengo Therapeutics?
Marengo aims to provide lifelong protection against cancer through its innovations in immunotherapy, leading to improved patient outcomes.
